DORMAN STUART 4

What Happened
Stuart Dorman, Chief Commercial Officer of IDEAYA Biosciences (IDYA), was granted 155,000 derivative shares (award) on January 30, 2026. The award was reported as acquired at $0.00, meaning no cash was paid at grant—this is a compensation award (e.g., RSUs or similar equity-based award) rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-30; Form 4 filed: 2026-02-02.
• Grant type: Derivative award (code A); 155,000 shares acquired at $0.00 (no cash consideration).
• Vesting (per footnote): 25% vests on the first anniversary measured from January 1, 2026 (the Vesting Commencement Date), then 1/48th of total shares vest monthly thereafter; 100% vests on the fourth anniversary.
• Shares owned after the transaction: not specified in the provided filing summary.
• No indication of a sale, cash exercise, gift, or tax-withholding event in this report.

Context
This is a standard equity compensation grant to an executive and does not represent an open-market buy or sell. Such awards typically align executive incentives with long-term shareholder value but do not immediately change public float or signal a near-term trading intent. The filing date (Feb 2, 2026) closely follows the transaction date (Jan 30, 2026), consistent with routine insider reporting timelines.